Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2017

Open Access 01-12-2017 | Primary research

The prognostic role of the cancer stem cell marker CD44 in ovarian cancer: a meta-analysis

Authors: Jiaying Lin, Ding Ding

Published in: Cancer Cell International | Issue 1/2017

Login to get access

Abstract

Background

CD44 has recently been reported as a cancer stem cell marker in ovarian cancer. However, the clinicopathological and prognostic value of this marker in ovarian cancer remains controversial; Here, we aimed to investigate the correlation between CD44 expression and the clinicopathological features or survival of ovarian cancer patients.

Methods

An extensive literature search in the PubMed, EMBASE, and Wanfang databases (up to June 1, 2016) was conducted to identify studies that assessed the clinical or prognostic significance of CD44 expression in ovarian cancer. A meta-analysis was then performed to clarify the association between CD44 expression and clinical outcomes of ovarian cancer patients.

Results

A total of 18 publications consisting of 2161 patients were included for this meta-analysis. Our data reveal that CD44-positive expression in ovarian cancers were significantly associated with a high TMN stage (pooled OR = 2.11, 95% CI 1.26–3.53, P = 0.004) and poor 5-year overall survival (RR = 1.42, 95% CI 1.01–2.00, P = 0.05). However, CD44 expression was not associated with tumor grade, lymphatic metastasis, age of the patients, residual tumor size, response to chemotherapy, or ascites volume (P > 0.05).

Conclusion

Detection of CD44 may be an effective tool for pathological diagnosis and prognostic prediction of ovarian cancer patients in clinical applications.
Literature
1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96.PubMedCrossRef
2.
3.
Zeimet A, Reimer D, Sopper S, Boesch M, Martowicz A, Roessler J, et al. Ovarian Cancer Stem Cells. Neoplasma. 2012;59(6):747.PubMedCrossRef
4.
Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res. 2011;71(11):3991–4001.PubMedPubMedCentralCrossRef
5.
Wang Y-C, Yo Y-T, Lee H-Y, Liao Y-P, Chao T-K, Su P-H, et al. ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome. Am J Pathol. 2012;180(3):1159–69.PubMedCrossRef
6.
Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, et al. Highly purified CD44 & plus; prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene. 2006;25(12):1696–708.PubMedCrossRef
7.
Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells. 2009;27(5):1006–20.PubMedPubMedCentralCrossRef
8.
Du L, Wang H, He L, Zhang J, Ni B, Wang X, et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res. 2008;14(21):6751–60.PubMedCrossRef
9.
Bourboulia D, Stetler-Stevenson WG, editors. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Seminars in cancer biology. New York: Elsevier; 2010.
10.
Wang SJ, Wong G, de Heer AM, Xia W, Bourguignon LY. CD44 variant isoforms in head and neck squamous cell carcinoma progression. Laryngoscope. 2009;119(8):1518–30.PubMedPubMedCentralCrossRef
11.
Yamada Y, Itano N, Narimatsu H, Kudo T, Hirohashi S, Ochiai A, et al. CD44 variant exon 6 expressions in colon cancer assessed by quantitative analysis using real time reverse transcriptase-polymerase chain reaction. Oncol Rep. 2003;10(6):1919–24.PubMed
12.
Afify AM, Craig S, Paulino AF, Stern R. Expression of hyaluronic acid and its receptors, CD44 s and CD44v6, in normal, hyperplastic, and neoplastic endometrium. Ann Diagn Pathol. 2005;9(6):312–8.PubMedCrossRef
13.
Afify AM, Ferguson AW, Davila RM, Werness BA. Expression of CD44S and CD44v5 is more common in stage III than in stage I serous ovarian carcinomas. Appl Immunohistochem Mol Morphol. 2001;9(4):309–14.PubMedCrossRef
14.
Dong W-G, Sun X-M, Yu B-P, Luo H-S, Yu J-P. Role of VEGF and CD44v6 in differentiating benign from malignant ascites. World J. 2003;9(11):2596–600.
15.
Cho EY, Choi Y, Chae SW, Sohn JH, Ahn GH. Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms. Pathol Int. 2006;56(2):62–70.PubMedCrossRef
16.
17.
Tjhay F, Motohara T, Tayama S, Narantuya D, Fujimoto K, Guo J, et al. CD44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer. Cancer Sci. 2015;106(10):1421–8.PubMedPubMedCentralCrossRef
18.
Chen H, Hao J, Wang L, Li Y. Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression. Br J Cancer. 2009;101(3):432–40.PubMedPubMedCentralCrossRef
19.
Gao Y, Foster R, Yang X, Feng Y, Shen JK, Mankin HJ, et al. Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer. Oncotarget. 2015;6(11):9313–26.PubMedPubMedCentralCrossRef
20.
Zhou L, Jiang Y, Yan T, Di G, Shen Z, Shao Z, et al. The prognostic role of cancer stem cells in breast cancer: a meta-analysis of published literatures. Breast Cancer Res Treat. 2010;122(3):795–801.PubMedCrossRef
21.
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–34.PubMedCrossRef
22.
Hong SC, Song JY, Lee JK, Lee NW, Kim SH, Yeom BW, et al. Significance of CD44v6 expression in gynecologic malignancies. J Obstet Gynaecol Res. 2006;32(4):379–86.PubMedCrossRef
23.
Liu M, Mor G, Cheng H, Xiang X, Hui P, Rutherford T, et al. High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancer. Reprod Sci. 2013;20(5):605–15.PubMedPubMedCentralCrossRef
24.
Rodriguez-Rodriguez L, Sancho-Torres I, Mesonero C, Gibbon D, Shih W, Zotalis G. The CD44 receptor is a molecular predictor of survival in ovarian cancer. Med Oncol. 2003;20(3):255–63.PubMedCrossRef
25.
Ross JS, Sheehan CE, Williams SS, Malfetano JH, Szyfelbein WM, Kallakury BV. Decreased CD44 standard form expression correlates with prognostic variables in ovarian carcinomas. Am J Clin Pathol. 2001;116(1):122–8.PubMedCrossRef
26.
Sillanpää S, Anttila MA, Voutilainen K, Tammi RH, Tammi MI, Saarikoski SV, et al. CD44 expression indicates favorable prognosis in epithelial ovarian cancer. Clin Cancer Res. 2003;9(14):5318–24.PubMed
27.
Steffensen KD, Alvero AB, Yang Y, Waldstrøm M, Hui P, Holmberg JC, et al. Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. J Oncol. 2011;2011:941876.CrossRef
28.
Wang H, Tan M, Zhang S, Li X, Gao J, Zhang D, et al. Expression and significance of CD44, CD47 and c-met in ovarian clear cell Carcinoma. Int J Mol Sci. 2015;16(2):3391–404.PubMedPubMedCentralCrossRef
29.
Zhang J, Chang B, Liu J. CD44 standard form expression is correlated with high-grade and advanced-stage ovarian carcinoma but not prognosis. Human Pathol. 2013;44(9):1882–9.CrossRef
30.
Zhu L-C, Gao J, Hu Z-H, Schwab CL, Zhuang H-Y, Tan M-Z, et al. Membranous expressions of Lewis y and CAM-DR-related markers are independent factors of chemotherapy resistance and poor prognosis in epithelial ovarian cancer. Am J Cancer Res. 2015;5(2):830.PubMedPubMedCentral
31.
Xu YX. Expression and significance of CD44v6 and PCNA in Ovarian Carcinoma [D]. Dalian: Dalian medical university; 2009.
32.
Li HZ, Li WW, Wei SP, Bo YS, Han YJ, Li RY. Study on the expression of CDl33, CD44 and Notchl in ovarian epithelial carcinoma. China Med Herald. 2012;9(19):21–3.
33.
Jiang YM, Chen AP. The significance of Ezrin and CD44 expression in Ovarian Cancer. Eval Anal Drug-Use Hosp China. 2010;4:344–6.
34.
Zhong JX, Shi GS. Role of CD44v6 in ovarian cancer. J Nantong Univ. 2001;21(2):135–6.
35.
36.
Zhang G, Wang Z, Luo W, Jiao H, Wu J, Jiang C. Expression of potential cancer stem cell marker ABCG2 is associated with malignant behaviors of hepatocellular carcinoma. Gastroenterol Res Pract. 2013;2013:782581.PubMedPubMedCentral
37.
Tummala M, McGuire W. Recurrent ovarian cancer. Clin Adv Hematol Oncol. 2005;3(9):723–36.PubMed
38.
Nihei Z, Ichikawa W, Kojima K, Togo S, Miyanaga T, Hirayama R, et al. The positive relationship between the expression of CD44 variant 6 and prognosis in colorectal cancer. Surg Today. 1996;26(9):760–1.PubMedCrossRef
39.
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci. 2003;100(7):3983–8.PubMedPubMedCentralCrossRef
40.
Hong SP, Wen J, Bang S, Park S, Song SY. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer. 2009;125(10):2323–31.PubMedCrossRef
41.
Gallatin WM, Weissman IL, Butcher EC. A cell-surface molecule involved in organ-specific homing of lymphocytes. Nature. 1982;304(5921):30–4.CrossRef
42.
Idzerda RL, Carter WG, Nottenburg C, Wayner EA, Gallatin WM, St John T. Isolation and DNA sequence of a cDNA clone encoding a lymphocyte adhesion receptor for high endothelium. Proc Natl Acad Sci. 1989;86(12):4659–63.PubMedPubMedCentralCrossRef
43.
Liang Y, Fang T, Xu H, Zhuo Z. Expression of CD44v6 and Livin in gastric cancer tissue. Chin Med J. 2012;125(17):3161–5.PubMed
44.
Zhang Y, Wei J, Wang H, Xue X, An Y, Tang D, et al. Epithelial mesenchymal transition correlates with CD24 + CD44 + and CD133 + cells in pancreatic cancer. Oncol Rep. 2012;27(5):1599–605.PubMed
45.
Cho SH, Park YS, Kim HJ, Kim CH, Lim SW, Huh JW, et al. CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion. Int J Oncol. 2012;41(1):211–8.PubMed
46.
Biddle A, Gammon L, Fazil B, Mackenzie IC. CD44 staining of cancer stem-like cells is influenced by down-regulation of CD44 variant isoforms and up-regulation of the standard CD44 isoform in the population of cells that have undergone epithelial-to-mesenchymal transition. PLoS ONE. 2013;8(2):e57314.PubMedPubMedCentralCrossRef
47.
Zöller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer. 2011;11(4):254–67.PubMedCrossRef
Metadata
Title
The prognostic role of the cancer stem cell marker CD44 in ovarian cancer: a meta-analysis
Authors
Jiaying Lin
Ding Ding
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2017
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-016-0376-4

Other articles of this Issue 1/2017

Cancer Cell International 1/2017 Go to the issue

Primary research

Circulating tumor microemboli (CTM) and vimentin+ circulating tumor cells (CTCs) detected by a size-based platform predict worse prognosis in advanced colorectal cancer patients during chemotherapy

Review

Targeting deubiquitinating enzymes in cancer stem cells

Primary Research

Growth of MCF-7 breast cancer cells and efficacy of anti-angiogenic agents in a hydroxyethyl chitosan/glycidyl methacrylate hydrogel

Research article

DMD transcripts in CRL-2061 rhabdomyosarcoma cells show high levels of intron retention by intron-specific PCR amplification

Primary Research

MiR-34a and miR-206 act as novel prognostic and therapy biomarkers in cervical cancer

Primary research

Role of CYP2E1 polymorphisms in breast cancer: a systematic review and meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits